(Il Sole 24 Ore Radiocor) - Milano, 30 mar - Insilico Medicine, a US clinical-stage biotechnology company powered by generative artificial intelligence (AI) and automation, announced an up to 2.75 billion dollar drug discovery collaboration with Eli Lilly that uses Insilico's AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas.

Under the terms of the agreement, Insilico is eligible to receive an 115 million dollars upfront payment, followed by development, regulatory, and commercial milestones, as well as tiered royalties on future sales.

The agreement grants Lilly an exclusive worldwide license for the development, manufacturing, and commercialization of potentially best-in-class, novel oral therapeutics in preclinical development for certain indications.

In addition, Insilico and Lilly will collaborate on multiple R&D programs focused on targets selected by Lilly, by combining Insilico's Pharma.AI platforms with Lilly's.

development capabilities and deep disease-area expertise.

(RADIOCOR) 30-03-26 09:12:32 (0130) 5 NNNN